Autoimmune and inflammatory disorder biologicals will power biotech market growth through to 2010

Journal of Commercial Biotechnology

Volumn 12, Issue 3, 2006, Pages 237-241

  Churchill, Clare A C ^a   Belsey, Mark J ^a  

^a Healthcare Competitive Intelligence Team ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY THERAPEUTICS; ARTHRITIS; AUTOIMMUNE DISORDER BIOLOGICALS; BIOTECH MARKET GROWTH; INFLAMMATORY DISORDER BIOLOGICALS;

ANTIBODIES; BIOLOGY; IMMUNOLOGY;

BIOTECHNOLOGY;

ADALIMUMAB; ALEFACEPT; BIOLOGICAL PRODUCT; CYCLOOXYGENASE 2 INHIBITOR; EFALIZUMAB; ETANERCEPT; HYBRID PROTEIN; IMMUNOGLOBULIN; INFLIXIMAB; RETINOID; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR;

ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; BIOTECHNOLOGY; CROHN DISEASE; DRUG MARKETING; HEALTH CARE; HUMAN; INFLAMMATORY DISEASE; LICENSING; MERGERS AND ACQUISITIONS; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

EID: 34447268007     PISSN: 14628732     EISSN: None     Source Type: Journal    
DOI: 10.1057/palgrave.jcb.3040172     Document Type: Article

References (5)

1. Belsey, M. and Pavlou, A. (2005), 'Leading therapeutic recombinant protein sales forecast and analysis to 2010', J. Comm. Biotechnol. Vol. 12, pp. 69-73.
2. URL: http://www.cdc.gov/arthritis/data_statistics/ arthritis_related_statistics.htm
3. Radulescu, M., Diepgen, T. L., Weisshaar, E. and Williams, H. (2003), 'What makes a good prevalence survey', in Williams, H. C., Bigby, M., Diepgen, T. L., Herxheimer, A., Naldi, L. and Rzany, B. Eds, 'Evidence-based Dermatology', BMJ Books, London.
4. The National Women's Health Information Center (NWHIC), US Dept of Health and Human Services (URL: http://www.hhs.gov).
5. Loftus, E. V., Silverstein, M. D., Sandborn, W. J., Tremaine, W. J., Harmsen, W. S. and Zinsmeister, A. R. (1998), 'Crohn's disease in Olmsted County, Minnesota, 1940-1993: Incidence, prevalence, and survival', Gastroenterology, Vol. 114, pp. 1161-1168.